Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer

Samsung Medical Center27 enrolled

Overview

We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Locally Advanced Stage III or IV Thymic Cancer

Interventions

neoadjuvant docetaxel/cisplatinDRUG

3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed thymic carcinoma * surgically inoperable Masaoka stage III or IV * ECOG 0-2 * at least one measurable disease Exclusion Criteria: * previous myocardiac infarct history within 1 year before the enrollment.

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Complete resection rate

Time frame: 4-8 weeks later after completion of neoadjuvant chemotherapy

Secondary Outcomes

the number of patients with adverse events

Time frame: from enrollment to 6 months after completion of chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.